
Rachel B Issaka

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7032884/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Towards health equity: the urgent need for upstream intervention studies in gastroenterology and hepatology. The Lancet Gastroenterology and Hepatology, 2022, 7, 203-204.	3.7	3
2	Barriers associated with inadequate follow-up of abnormal fecal immunochemical test results in a safety-net system: A mixed-methods analysis. Preventive Medicine Reports, 2022, 28, 101831.	0.8	2
3	Standardized Workflows Improve Colonoscopy Follow-Up After Abnormal Fecal Immunochemical Tests in a Safety-Net System. Digestive Diseases and Sciences, 2021, 66, 768-774.	1.1	9
4	What Multilevel Interventions Do We Need to Increase the Colorectal Cancer Screening Rate to 80%?. Clinical Gastroenterology and Hepatology, 2021, 19, 633-645.	2.4	22
5	Selection of patients for large mailed fecal immunochemical test colorectal cancer screening outreach programs: A systematic review. Journal of Medical Screening, 2021, 28, 096914132199748.	1.1	2
6	Model-Based Estimation of Colorectal Cancer Screening and Outcomes During the COVID-19 Pandemic. JAMA Network Open, 2021, 4, e216454.	2.8	32
7	The Path to Gastroenterology and Hepatology Leadership: Inadvertently Perpetuating the Glass Ceiling and Sticky Floor. Gastroenterology, 2021, 160, 2201-2202.	0.6	6
8	Analysis of Speaker Introduction Formality by Gender at the American College of Gastroenterology 2020 Annual Scientific Meeting. Digestive Diseases and Sciences, 2021, , 1.	1.1	2
9	Perceptions on Barriers and Facilitators to Colonoscopy Completion After Abnormal Fecal Immunochemical Test Results in a Safety Net System. JAMA Network Open, 2021, 4, e2120159.	2.8	14
10	Financial Incentives to Improve Colorectal Cancer Screening—Time to Cut Our Losses. JAMA Network Open, 2021, 4, e2122661.	2.8	4
11	Advancing diversity: the role of international medical graduates. The Lancet Gastroenterology and Hepatology, 2021, 6, 980-981.	3.7	8
12	Effectiveness and Cost of Organized Outreach for Colorectal Cancer Screening: A Randomized, Controlled Trial. Journal of the National Cancer Institute, 2020, 112, 305-313.	3.0	46
13	Effectiveness of a mailed fecal immunochemical test outreach: a Medicare Advantage pilot study. Therapeutic Advances in Gastroenterology, 2020, 13, 175628482094538.	1.4	12
14	Advanced Notification Calls Prior to Mailed Fecal Immunochemical Test in Previously Screened Patients: a Randomized Controlled Trial. Journal of General Internal Medicine, 2020, 35, 2858-2864.	1.3	3
15	Impact of COVID-19 on colorectal cancer disparities and the way forward. Gastrointestinal Endoscopy, 2020, 92, 946-950.	0.5	70
16	Mailed fecal immunochemical test outreach for colorectal cancer screening: Summary of a Centers for Disease Control and Prevention–sponsored Summit. Ca-A Cancer Journal for Clinicians, 2020, 70, 283-298.	157.7	75
17	Racial Disparities in Colorectal Cancer Mortality: the Role of Endoscopy Wait-Time and Stage at Diagnosis. Journal of Racial and Ethnic Health Disparities, 2020, 7, 967-974.	1.8	1
18	Colorectal Cancer Screening and Prevention in the COVID-19 Era. JAMA Health Forum, 2020, 1, e200588.	1.0	41

RACHEL B ISSAKA

#	Article	IF	CITATIONS
19	Population health interventions to improve colorectal cancer screening by fecal immunochemical tests: A systematic review. Preventive Medicine, 2019, 118, 113-121.	1.6	77
20	Missed Opportunities in Colorectal Cancer Prevention in Patients With Inadequate Bowel Preparations. Clinical Gastroenterology and Hepatology, 2018, 16, 1533-1534.	2.4	2
21	Low-Value Colorectal Cancer Screening. JAMA Network Open, 2018, 1, e185445.	2.8	2
22	Yield of Colonoscopy After a Positive Result From a Fecal Immunochemical Test OC-Light. Clinical Gastroenterology and Hepatology, 2018, 16, 1593-1597.e1.	2.4	16
23	Inadequate Utilization of Diagnostic Colonoscopy Following Abnormal FIT Results in an Integrated Safety-Net System. American Journal of Gastroenterology, 2017, 112, 375-382.	0.2	63